Immunotherapy

Positive results in first-in-U.S. trial of CRISPR-edited immune cells

Genetically editing a cancer patient’s immune cells using CRISPR/Cas9 technology, then infusing those cells back into the patient appears safe and feasible based on early data from the first-ever clinical trial to test the approach in humans in the United States.

Penn Today Staff

CAR T cell therapy may be harnessed to treat heart disease

Penn Med researchers used genetically modified T cells to improve heart function in an animal model after cardiac injury, a step forward in expanding the use of the technology to treating, or even reversing, heart failure.

Penn Today Staff